Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.51 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.51 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789885 | 1.00 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL457834 | 0.91 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL457833 | 0.91 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL3380397 | 0.91 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL3778182 | 0.91 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL8557325 | 0.88 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL8557320 | 0.88 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL5051948 | 0.87 | CYSLTR2 (0.57) | CYSLTR1CYSLTR2 | |
| SCHEMBL5498774 | 0.87 | CYSLTR2 (0.57) | CYSLTR1CYSLTR2 | |
| SCHEMBL5051946 | 0.87 | CYSLTR2 (0.57) | CYSLTR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858793-B2 | Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates | SATYANARAYANA CHAVA | 2010-12-28 | — | — | US | claimed |
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | SATYANARAYANA CHAVA | 2008-11-06 | — | — | US | claimed |
| US-20110137039-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MYLAN LABORATORIES LIMITED (IN) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | HTR3C, HTR3B, TPMT | CYSLTR1 3478/4885CYSLTR2 2907/4885ABCC1 3315/4885 |
| US-20110137039-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MPST, CMA1, LTC4S | CYSLTR1 4/4885CYSLTR2 5/4885ABCC1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.